… In this review we attempt to give an overview on recent preclinical and clinical studies that
have addressed the role of PI3K/AKT pathway and PI3K/AKT inhibitors in pancreatic cancer. …

… by low phospho-Akt. Remarkably, Akt inhibitors reduced cancer cell growth in monolayers
… Inhibition of Akt decreased cell migration and invasion, which was additionally reduced by …

… More recently, olaparib, a PARP inhibitor, has received FDA approval for pancreatic cancer
patients harboring germline BRCA1 or BRCA2 mutations, presenting the first biomarker-…

… that the inhibition of PI3K/AKT sensitises pancreatic cancer to … that a survival signal from
AKT activation is mediated by NF-… , inhibition of this pathway sensitises pancreatic cancer cells …

… Therefore, FKBP5 could be a tumor suppressor in pancreatic cancer and it could also be a …
a first line treatment for pancreatic cancer. Our findings that a specific Akt inhibitor can reverse …

… Furthermore, an ongoing trial in pancreatic cancer is assessing the combination of RX-0201
and gemcitabine Citation[57,59]. A liposomal formulation of RX-0201 (RX-0201-nano) is …

… , as it was demonstrated to be aberrantly regulated in pancreatic cancer cells. The present …
the novel Akt inhibitor MK‑2206 in human pancreatic cancer cell lines. Pancreatic cancer cell …

… These studies will provide the necessary rationale for further development of Akt
inhibition in pancreatic cancer by allowing appropriate tumor and chemotherapy selection. …

… patients (two of which were diagnosed with pancreatic cancer) were enrolled. The aim of …
treating pancreatic cancer patients. In this review, we focus on PI3K/AKT/mTOR inhibitors that …

… Akt inhibition induces both autophagy and then subsequent apoptotic cell death in pancreatic
cancer cells, while mTOR inhibition … autophagy induced following Akt inhibition is required …